Jan 9, 2019 8:00 am EST Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
Dec 31, 2018 8:00 am EST Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan
Dec 20, 2018 8:00 am EST Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia
Oct 11, 2018 7:30 am EDT Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
Oct 4, 2018 9:35 am EDT Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares
Oct 3, 2018 4:23 pm EDT Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares
Oct 1, 2018 5:00 pm EDT Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures